Therapeutic Advances in Medical Oncology最新文献

{"title":"Bone metastasis in follicular dendritic cell sarcoma-a rare site in a rare disease: case report and review of literature.","authors":"Tsielestina Poulli, Christos Cortas, Antonios Neokleous, Irene Tsappa, Pampina Pilavaki, Morfo Georgiou, Chloe Symeonidou, Nicos Katodritis, Anastasia Constantinidou","doi":"10.1177/17588359251318863","DOIUrl":"10.1177/17588359251318863","url":null,"abstract":"<p><p>Follicular dendritic cell sarcoma (FDCS) is a rare sarcoma subtype, presenting as a relatively indolent disease in most cases. Given its rarity, clinicopathological characteristics and behavior as well as treatment, are reported in the literature through case reports and case series. Bone metastasis in FDCS is extremely rare and the outcome of the disease in this group of patients is unknown. We report one case of FDCS with bone involvement as the first site of metastasis. We present the progression of the disease over a period of almost a decade in a detailed manner, particularly the therapies used including immunotherapy with checkpoint inhibitors. In parallel, we provide a comparison with other cases of FDCS metastatic to the bone (total of eight cases) through a systematic review of the literature on the clinical and pathological manifestations as well as the outcomes of all such cases reported to date, to the best of our knowledge. These cases highlight the challenges associated with setting the correct diagnosis at presentation, the lack of evidence to support the role of adjuvant therapy following primary surgery but also the role and/or sequence of systemic options in the advanced setting.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251318863"},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study.","authors":"Die Sang, Yanfang Su, Yurong Zhang, Yanfeng Guan, Shanmin Fan, Jintao Zhang, Lijun Zheng, Yanling Wang, Ying Guo, Zixuan Lei, Man Li, Peng Yuan","doi":"10.1177/17588359251318853","DOIUrl":"10.1177/17588359251318853","url":null,"abstract":"<p><strong>Objective: </strong>Limited real-world efficacy and safety data exist regarding the use of trastuzumab deruxtecan (T-DXd) in the Chinese population with human epidermal growth factor receptor (HER2)-positive and HER2-low advanced breast cancer (BC). This multicenter, observational, real-world study aimed to evaluate the efficacy and safety of T-DXd for the treatment of Chinese patients with HER2-positive and HER2-low advanced BC.</p><p><strong>Methods: </strong>The medical records of 61 patients were collected from The Second Hospital of Dalian Medical University, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing Jingxin Hospital, and Cancer Hospital of the Chinese Academy of Medical Sciences. The primary endpoint of the study was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), time to response (TTR), and safety. PFS and OS were analyzed using the Kaplan-Meier method and log-rank test.</p><p><strong>Results: </strong>The primary endpoint, PFS was 10.51 months (95% confidence interval (CI), 3.02-NE) in the HER2-low group and 10.18 months (95% CI, 3.88-NE) in the HER2-positive group. Regarding the secondary endpoints in the HER2-low and HER2-positive groups, OS data were immature, ORR rates were 37.93% and 62.50%, DCR rates were 79.31% and 87.50%, and the median TTR rates were 1.28 and 1.31 months, respectively. In the subgroup analysis, front-line treatment with T-DXd was associated with increased beneficial effects. The primary adverse events (AEs) related to T-DXd treatment were gastrointestinal reactions and bone marrow suppression, which were predominantly grades 1-2, with no severe grade 4/5 AEs reported, only one patient developed infectious pneumonia.</p><p><strong>Conclusion: </strong>This study was the first multicenter, real-world study of T-DXd for advanced BC in China. The findings demonstrated that T-DXd may be an effective antitumor treatment with controllable adverse reactions in patients with advanced BC irrespective of HER2 expression levels.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251318853"},"PeriodicalIF":4.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferroptosis-related genes as prognostic markers for survival and immunotherapy in triple-negative breast cancer: analysis of public databases and a single institution.","authors":"Yizhao Xie, Zhonghua Tao, Biyun Wang, Yannan Zhao, Xinyu Chen, Bin Li, Jinyan Wang, Guangliang Chen, Xichun Hu","doi":"10.1177/17588359251322291","DOIUrl":"10.1177/17588359251322291","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis plays a vital role in cancer development and treatment. The relationship between ferroptosis-related genes and breast cancer prognosis, as well as immunotherapy outcomes, remains unknown.</p><p><strong>Objectives: </strong>To evaluate the prognostic value of ferroptosis-related genes in breast cancer.</p><p><strong>Methods: </strong>We conducted differential expressions and prognostic analysis for ferroptosis-related genes on public databases and breast cancer patients in our center and analyzed their predictive value for immunotherapy of breast cancer patients.</p><p><strong>Results: </strong>We identified prognostic ferroptosis-related genes, constructed a nomogram, and validated key genes using patient data from our center. We also investigated ferroptosis-related genes significantly associated with immune infiltration and identified <i>FTH1</i> as a promising biomarker for triple-negative breast cancer immunotherapy.</p><p><strong>Conclusion: </strong>Ferroptosis-related genes had potential prognostic value and predictive value for breast cancer immunotherapy.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251322291"},"PeriodicalIF":4.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review.","authors":"Igor Gomez-Randulfe, Helen Lavender, Stefan Symeonides, Fiona Blackhall","doi":"10.1177/17588359251316988","DOIUrl":"https://doi.org/10.1177/17588359251316988","url":null,"abstract":"<p><p>Therapeutic cancer vaccines aim to generate a robust immune response against tumour-associated antigens (TAAs) or tumour-specific antigens. While their safety is well established, their efficacy as monotherapy remains limited due to factors such as self-tolerance to TAAs and the immunosuppressive tumour microenvironment. Combining cancer vaccines with systemic anticancer therapies (SACTs) offers a promising strategy to improve efficacy. However, the optimal timing and combination with immune checkpoint inhibitors (ICIs) and chemotherapy to enhance immunogenicity are not yet fully understood. This review aims to assess the evidence regarding the immunogenicity of antiviral and anticancer vaccines when combined with SACTs, including chemotherapy and ICIs, with a particular focus on the timing of vaccine administration relative to SACT. Additionally, we evaluate the impact of steroids on immunogenicity. Our findings suggest that the timing of vaccine administration is critical, with improved immunogenic responses observed when vaccines are administered at nadir (15 days post-chemotherapy). Certain chemotherapies, such as low-dose metronomic cyclophosphamide and paclitaxel, demonstrate potential for immunomodulation, enhancing T-cell responses when combined with vaccines. Conversely, steroids may reduce immunogenicity. The combination of ICIs with cancer vaccines shows evidence of a synergistic effect, with concurrent administration generally yielding better outcomes than sequential approaches. Prospective trials exploring various timings and sequences are essential to optimize the efficacy of anticancer vaccines.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251316988"},"PeriodicalIF":4.3,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report.","authors":"Kasey C Fitzsimmons, Michelle A Fajardo, Zorawar Noor","doi":"10.1177/17588359251322003","DOIUrl":"10.1177/17588359251322003","url":null,"abstract":"<p><p>We present a case report of a patient with metastatic small cell neuroendocrine carcinoma of the breast (SCNCB), a high-grade neuroendocrine triple-negative breast cancer, who achieved a complete response after two cycles of sacituzumab govitecan-hziy (SG) (Trodelvy) as third-line systemic therapy. She originally presented with estrogen receptor-positive disease, and we were able to clearly demonstrate transformation into triple-negative SCNCB via serial tissue biopsies. This is the first reported case of SG for SCNCB, and it shows an outstanding response in a patient who had undergone prior systemic therapies. Clinical trials are needed to address the potential role of TROP2 inhibition and the use of SG as a therapy for SCNCB.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251322003"},"PeriodicalIF":4.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CART-induced eosinophilic colitis with good response to corticosteroids and infliximab: a case report.","authors":"Garrett T Coleman, Yinghong Wang","doi":"10.1177/17588359251320736","DOIUrl":"10.1177/17588359251320736","url":null,"abstract":"<p><p>Chimeric antigen receptor T-cell (CART) therapy is an efficacious immunotherapy with known multi-organ toxicities, including gastrointestinal adverse events (GI-AEs). Eosinophilic colitis (EoC) is the inflammation of the intestine with diffuse eosinophilic infiltration. We present the case of a 66-year-old male who presented with diarrhea and biopsy-proven EoC two months after CART therapy for recurrent multiple myeloma (MM) and achieved a favorable response following corticosteroids and infliximab. A 66-year-old male with a past medical history of MM presented with watery stools 5-6 times per day. The patient was diagnosed with MM 10 years ago and achieved remission following an autologous stem cell transplant and maintenance chemotherapy. Three years ago, the patient developed recurrent MM, received CART therapy, and achieved cancer remission. Two months following CART therapy, he presented to the local emergency department (ED) for several weeks of diarrhea with a negative infectious workup. This disease course was associated with several ED visits and hospital admissions. He was started on budesonide without a significant response. Subsequent colonoscopy and resultant histology were consistent with EoC. The patient was started on an IV steroid with infliximab and a prednisone taper for refractory EoC. Following his third dose of infliximab and completing his prednisone taper, he reported a return to baseline symptomatically. CART is an immunotherapy associated with GI-AEs and requires corticosteroids or other immunosuppressants in select cases. EoC has been associated with cancer and cancer therapy and may require biological agents. Early recognition and treatment of immunotherapy toxicities are essential for successful management of gastrointestinal adverse events.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251320736"},"PeriodicalIF":4.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023.","authors":"Keitaro Shimozaki, Akira Ooki, Koichiro Yoshino, Mikako Tamba, Shohei Udagawa, Hiroki Osumi, Shota Fukuoka, Izuma Nakayama, Takeru Wakatsuki, Mariko Ogura, Daisuke Takahari, Eiji Shinozaki, Keisho Chin, Kensei Yamaguchi","doi":"10.1177/17588359251322670","DOIUrl":"10.1177/17588359251322670","url":null,"abstract":"<p><strong>Background: </strong>Although the emergence of immunotherapy has benefited patients with advanced gastric cancer (AGC), the magnitude of the benefit among real-world patients with HER2-negative AGC remains unclear.</p><p><strong>Objectives: </strong>The current study aimed to evaluate the treatment features across various immunotherapy approval periods and investigate the utility of immunotherapy for patients with HER2-negative AGC in daily practice.</p><p><strong>Design: </strong>Retrospective observational study.</p><p><strong>Methods: </strong>We retrospectively evaluated the clinical outcomes of patients with HER2-negative AGC who received first-line platinum-based chemotherapy between 2011 and 2023 across different periods of immunotherapy approval in Japan: Group A (pre-immunotherapy approval): 2011-2017; Group B (approved for third-line treatment or later): 2018-2021; and Group C (approved for first-line treatment): 2022-2023.</p><p><strong>Results: </strong>A total of 949 patients were enrolled (<i>n</i> = 477, 344, and 128 for Groups A, B, and C, respectively). Patient characteristics were comparable between the three groups, except for the proportion of those aged ⩾75 years (<i>p</i> = 0.002), prior gastrectomy (<i>p</i> = 0.03), and liver metastases (<i>p</i> = 0.0005). The median overall survival (OS) was 16.2, 15.2, and 21.3 months in Groups A, B, and C, respectively, with no significant difference between the groups (log-rank <i>p</i> = 0.50). Patients who received first-line immunotherapy plus chemotherapy (<i>n</i> = 173) showed significantly better OS than did those who did not receive any immunotherapy-containing treatment from 2011 to 2017 (<i>n</i> = 382; hazard ratio (HR), 0.78; 95% confidence interval (CI), 0.61-0.99; <i>p</i> = 0.04). Multivariate analysis showed that the use of first-line immunotherapy was not significantly associated with worse OS, whereas the use of any-line immunotherapy was significantly associated with prognosis (HR, 0.54; 95% CI, 0.47-0.63; <i>p</i> < 0.0001). The proportion of patients receiving any second-line treatment was comparable between the groups: 76%, 80%, and 71%, respectively.</p><p><strong>Conclusion: </strong>Our study suggests that immunotherapy has a moderate impact on improving the survival of real-world patients with HER2-negative AGC, highlighting the need for appropriate treatment strategies, including efforts to identify biomarkers and the development of other agents.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251322670"},"PeriodicalIF":4.3,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adopting tomorrow's therapies today: a perspective review of adoptive cell therapy in lung cancer.","authors":"Faith Abodunrin, Daniel J Olson, Oluwatosin Emehinola, Christine M Bestvina","doi":"10.1177/17588359251320280","DOIUrl":"10.1177/17588359251320280","url":null,"abstract":"<p><p>Lung cancer is the leading cause of all cancer-related deaths in the United States and remains a global health challenge. While targeted therapy has revolutionized the treatment landscape of nonsmall cell lung cancer, many patients lack actionable mutations. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), have significantly impacted outcomes in lung cancer in the last decade. Some patients, however, never respond or become refractory to ICIs. Newer therapies aimed at augmenting the immune system and enhancing antitumor effects are currently being explored. Adoptive cell therapy (ACT) employs T cells isolated from either tumors or peripheral blood and often engineers them to effect antitumor immune response. Chimeric antigen receptor T (CAR-T) cell therapy, engineered T cell receptor therapy, and tumor-infiltrating lymphocytes are examples of adoptive cellular therapies. CAR-T cell therapy has been successful in the treatment of hematological malignancies with several CAR products gaining approval in the treatment of refractory blood cancers. The success of ACTs in hematological cancers has fueled research into the role of these therapies in solid cancers including lung cancer. Many trials have had early promising results, with many clinical trials currently enrolling. There are many limitations to the efficacy of ACTs, as well as risks and benefits with the individual subtypes of ACT. With growing knowledge about tumor antigens and more advanced cell engineering, there is potential for ACT to result in durable responses in immunologically \"cold\" tumors. Here, we review the major subtypes of ACTs, evidence supporting their use in lung cancer, challenges, and future perspectives in ACTs. Additionally, we include T cell engagers and mRNA vaccine studies and potential combinatorial strategies in lung cancer.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251320280"},"PeriodicalIF":4.3,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding and treating HPV-associated oropharyngeal carcinoma: insights from a MedNewsWeek Keynote lecture by Dr Theodoros N. Teknos and literature review.","authors":"Viviana Cortiana, Soumiya Nadar, Jade Gambill, Diksha Mahendru, Adhith Theyver, Helena S Coloma, Chandler H Park, Yan Leyfman","doi":"10.1177/17588359251322290","DOIUrl":"10.1177/17588359251322290","url":null,"abstract":"<p><p>Oropharyngeal carcinoma, a type of head and neck cancer (HNC), is an emerging malignancy associated with low survival rates. It typically affects older males and correlates with smoking, drinking, and lower socioeconomic conditions. Traditional treatments such as surgery have often yielded limited outcomes. However, recent insights, particularly those emphasized by Dr Teknos in his Keynote Conference at MedNews Week, have sparked a deeper exploration into alternative and more promising treatment methods. A comprehensive literature review was conducted to explore this subject further. One such approach, demonstrated by the UMCC 9921 trial, involves a comprehensive protocol starting with induction chemotherapy. This initial phase aims to reduce tumor burden and assess response to treatment. Based on the individual outcomes, patients then undergo concurrent chemoradiation or salvage surgery. This strategy has significantly improved survival rates, especially in human papillomavirus (HPV)-positive patients, showcasing the potential of tailored treatments. While these advancements are promising, long-term complications such as dysphagia and osteoradionecrosis remain a cause of concern. The rise of HPV-related head and neck squamous cell carcinoma has further changed how risk factors and treatment outcomes are viewed. HPV-positive cancers have unique characteristics and respond well to modern therapies. Researchers are investigating biomarkers such as circulating HPV DNA and immunoglobulin J polypeptide expression, which could provide valuable insights into disease progression and pave the way for more targeted and effective treatment strategies. In addition, the use of existing medications, such as fenofibrate, to combat HPV infections illustrates the resourcefulness in repurposing specific treatments. Challenges persist, especially in the need for reliable biomarkers for early disease progression detection and monitoring. Deeper insights into viral-host interactions shape promising immunotherapy strategies that could revolutionize treatment approaches. Collaborative efforts between researchers, healthcare providers, and policymakers play a vital role in translating these advancements into substantial clinical benefits, improving outcomes and quality of life for individuals affected by HPV-related diseases. While HPV-associated HNCs present significant challenges, continuous research and innovative treatments offer hope for a brighter future in combating this growing epidemic and improving patient care.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251322290"},"PeriodicalIF":4.3,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11851760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143504336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of second primary cancer in young breast cancer survivors: an important yet overlooked issue.","authors":"Xinyi Liang, Yiwei Qin, Pengwei Li, You Mo, Dawei Chen","doi":"10.1177/17588359251321904","DOIUrl":"10.1177/17588359251321904","url":null,"abstract":"<p><p>Currently, female breast cancer (BC) represents the highest incidence of cancer globally. This trend has raised significant attention regarding breast cancer young women (BCYW). With advancements in treatment technology, BCYW survivors are living longer; however, the risk of developing or succumbing to a second primary cancer (SPC) has greatly increased. In addition, several factors, including age, menstrual cycle, hormonal changes, obesity, pregnancy, and breastfeeding, interact to influence the development of SPC in BCYW and make its treatment more difficult. This study investigates the relationship between BCYW and SPC, focusing on morbidity trends, pathological genomics, recurrence rates, survival times, treatment modalities, and physiological fertility. Most BCYW involve BRCA pathogenic variants or fall under triple-negative and human epidermal growth factor receptor 2-overexpressing subtypes, increasing the risk of SPC. While there are regional variations in survival time following the diagnosis of an SPC, the long-term survival outcomes remain unfavorable. In addition, the choice of treatment for BCYW survivors has a prolonged cumulative toxic effect. The combination of endocrine therapy and chemotherapy is effective in treating BC, but it simultaneously increases the risk of developing an SPC, specifically endometrial cancer. Furthermore, radiotherapy is associated with a heightened risk of contralateral BC and lung cancer. We aim to address existing gaps in the literature and to enhance awareness of the risks associated with SPC in BCYW, thereby offering valuable insights for clinical diagnosis and treatment.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251321904"},"PeriodicalIF":4.3,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}